{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:58:40Z","timestamp":1787655520308,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Urate-lowering therapy (ULT) plays a pivotal role in treating gout patients. Unfortunately, some patients receiving oral ULT fail to achieve the target serum urate levels of &lt; 6.8\u200amg\/dl, the solubility level of uric acid. Exogenous uricases, considered \u201cenzyme replacement therapy,\u201d are a therapeutic option for patients with uncontrolled gout in whom oral ULT has not been efficacious, is not tolerated, or is contraindicated, in some due to underlying comorbidities. Currently, two uricases are available: pegloticase and rasburicase. Pegloticase is indicated for treating uncontrolled gout, while rasburicase is used to prevent tumor lysis syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The main limitations of pegloticase include gout flares and infusion reactions, which are linked to the formation of antidrug antibodies. Immunomodulation and anti-inflammatory prophylaxis can help reduce these issues. New PEGylated uricases, including nanoencapsulated sirolimus combined with pegadricase (NASP) and PRX-115, are being developed and may offer improved options.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Exogenous uricases available and those under development are discussed, focusing on immunomodulation and anti-inflammatory prophylaxis to reduce flares, prevent antidrug antibody formation and infusion reactions, and mitigate loss of efficacy in patients with uncontrolled gout needing uricase replacement therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000001122","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:00:56Z","timestamp":1757329256000},"page":"422-429","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Updates in uricase therapy for gout"],"prefix":"10.1097","volume":"37","author":[{"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[{"name":"Harold J. Ardella T. and Helen T. Stevenson Presidential Chair in Rheumatology, Professor and Chief, Division of Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Research Assistant Professor, Division of Rheumatology, Department of Medicine, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"R1-20251007","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/ard.33.4.313","article-title":"Factors affecting urate solubility in vitro","volume":"33","author":"Kippen","year":"1974","journal-title":"Ann Rheum Dis"},{"key":"R2-20251007","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5582\/irdr.2022.01131","article-title":"Evaluation of the efficacy and safety of pegloticase for the treatment of chronic refractory gout through meta-analysis","volume":"12","author":"Fan","year":"2023","journal-title":"Intractable Rare Dis Res"},{"key":"R3-20251007","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1007\/s12325-025-03189-5","article-title":"Evaluation of real-world treatment patterns and healthcare resource utilization in patients with chronic refractory gout in the United States","volume":"42","author":"Kragh","year":"2025","journal-title":"Adv Ther"},{"key":"R4-20251007","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41584-023-01006-3","article-title":"Mechanisms and rationale for uricase use in patients with gout","volume":"19","author":"Schlesinger","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"R5-20251007","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"R6-20251007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"R7-20251007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semnephrol.2004.09.002","article-title":"Uric acid, evolution and primitive cultures","volume":"25","author":"Johnson","year":"2005","journal-title":"Semin Nephrol"},{"key":"R8-20251007","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1073\/pnas.1320393111","article-title":"Evolutionary history and metabolic insights of ancient mammalian uricases","volume":"111","author":"Kratzer","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"R9-20251007","doi-asserted-by":"crossref","first-page":"msab312","DOI":"10.1093\/molbev\/msab312","article-title":"Phylogenetic articulation of uric acid evolution in mammals and how it informs a therapeutic uricase","volume":"39","author":"Li","year":"2022","journal-title":"Mol Biol Evol"},{"key":"R10-20251007","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/rheumatology\/keq204","article-title":"Uric acid and evolution","volume":"49","author":"Alvarez-Lario","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"R11-20251007","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J Mol Evol"},{"key":"R12-20251007","doi-asserted-by":"crossref","first-page":"e0167935","DOI":"10.1371\/journal.pone.0167935","article-title":"A therapeutic uricase with reduced immunogenicity risk and improved development properties","volume":"11","author":"Nyborg","year":"2016","journal-title":"PLoS One"},{"key":"R13-20251007","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nsb1197-947","article-title":"Crystal structure of the protein drug urate oxidase-inhibitor complex at 2.05 A resolution","volume":"4","author":"Colloc\u2019h","year":"1997","journal-title":"Nat Struct Biol"},{"key":"R14-20251007","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/bj1870727","article-title":"Thermodynamics and stoicheiometry of the binding of substrate analogues to uricase","volume":"187","author":"Conley","year":"1980","journal-title":"Biochem J"},{"key":"R15-20251007","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/jps.21278","article-title":"The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics","volume":"97","author":"Fishburn","year":"2008","journal-title":"J Pharm Sci"},{"key":"R16-20251007","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1021\/acs.molpharmaceut.5b00144","article-title":"Anti-PEG IgM is a major contributor to the accelerated blood clearance of polyethylene glycol-conjugated protein","volume":"12","author":"Mima","year":"2015","journal-title":"Mol Pharm"},{"key":"R17-20251007","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154\u2013155","author":"Kozma","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"R18-20251007","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.4155\/fmc.14.125","article-title":"PEGylation and its impact on the design of new protein-based medicines","volume":"6","author":"Ginn","year":"2014","journal-title":"Future Med Chem"},{"key":"R19-20251007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jbspin.2012.01.004","article-title":"Therapeutic perspectives on uricases for gout","volume":"79","author":"Garay","year":"2012","journal-title":"Joint Bone Spine"},{"key":"R20-20251007","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-014-0255-7","article-title":"Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project","volume":"38","author":"Allen","year":"2015","journal-title":"Drug Saf"},{"key":"R21-20251007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd3349","article-title":"Pegloticase","volume":"10","author":"Schlesinger","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"R22-20251007","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"R23-20251007","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.xphs.2023.11.001","article-title":"Treatment-induced and preexisting antipeg antibodies: prevalence, clinical implications, and future perspectives","volume":"113","author":"Gaballa","year":"2024","journal-title":"J Pharm Sci"},{"key":"R24-20251007","doi-asserted-by":"crossref","first-page":"1232560","DOI":"10.3389\/fimmu.2023.1232560","article-title":"Glucose-6-phosphate dehydrogenase deficiency and long-term risk of immune-related disorders","volume":"14","author":"Israel","year":"2023","journal-title":"Front Immunol"},{"key":"R25-20251007","doi-asserted-by":"crossref","first-page":"101619","DOI":"10.1016\/j.siny.2025.101619","article-title":"Revised World Health Organization (WHO) classification of G6PD gene variants: relevance to neonatal hyperbilirubinemia","volume":"30","author":"Watchko","year":"2025","journal-title":"Semin Fetal Neonatal Med"},{"key":"R26-20251007","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.tips.2021.07.002","article-title":"Treatment strategies for glucose-6-phosphate dehydrogenase deficiency: past and future perspectives","volume":"42","author":"Garcia","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"R29-20251007","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"R30-20251007","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/art.22403","article-title":"Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout","volume":"56","author":"Sundy","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R31-20251007","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R32-20251007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R33-20251007","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s40744-024-00681-2","article-title":"Projected health and economic burden of comorbid gout and chronic kidney disease in a virtual US population: a microsimulation study","volume":"11","author":"Card-Gowers","year":"2024","journal-title":"Rheumatol Ther"},{"key":"R34-20251007","doi-asserted-by":"crossref","first-page":"e14993","DOI":"10.1111\/ctr.14993","article-title":"Pegloticase efficacy and safety in kidney transplant recipients; results of the phase IV, open-label PROTECT clinical trial","volume":"37","author":"Abdellatif","year":"2023","journal-title":"Clin Transplant"},{"key":"R35-20251007","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-017-1396-8","article-title":"Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout","volume":"19","author":"Calabrese","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"R36-20251007","doi-asserted-by":"crossref","first-page":"R60","DOI":"10.1186\/ar4497","article-title":"Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout","volume":"16","author":"Lipsky","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R37-20251007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11926-022-01055-9","article-title":"Expert opinion on pegloticase with concomitant immunomodulatory therapy in the treatment of uncontrolled gout to improve efficacy, safety, and durability of response","volume":"24","author":"Botson","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"R38-20251007","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar4500","article-title":"Induced and preexisting antipolyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients","volume":"16","author":"Hershfield","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R39-20251007","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/RHU.0000000000000200","article-title":"Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy","volume":"20","author":"Baraf","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"R40-20251007","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3899\/jrheum.200460","article-title":"Pegloticase in combination with methotrexate in patients with uncontrolled gout: a multicenter, open-label study (MIRROR)","volume":"48","author":"Botson","year":"2021","journal-title":"J Rheumatol"},{"key":"R41-20251007","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.semarthrit.2021.01.005","article-title":"The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review","volume":"51","author":"Keenan","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"R42-20251007","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/acr2.11578","article-title":"A Randomized, double-blind, placebo-controlled multicenter efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: 12-month findings","volume":"5","author":"Botson","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"R43-20251007","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/art.42335","article-title":"A randomized, placebo-controlled study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase: primary efficacy and safety findings","volume":"75","author":"Botson","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R44-20251007","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/acr.25361","article-title":"Real-world effectiveness of pegloticase associated with use of concomitant immunomodulatory therapy","volume":"76","author":"Holladay","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R45-20251007","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2020-eular.3893","article-title":"Immunomodulation co-therapy with pegloticase: database trends 2014-2019","volume":"79","author":"Lamoreaux","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R46-20251007","doi-asserted-by":"crossref","first-page":"e11789","DOI":"10.1002\/acr2.11789","article-title":"Pegloticase and methotrexate cotherapy in patients with uncontrolled gout with prior pegloticase monotherapy failure: findings of an open-label trial","volume":"7","author":"Troum","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"R47-20251007","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/art.41731","article-title":"Reducing immunogenicity of pegloticase with concomitant use of mycophenolate mofetil in patients with refractory gout: a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Khanna","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R48-20251007","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/annrheumdis-2020-eular.4642","article-title":"Companion immunosuppression with azathioprine increases the frequency of persistent responsiveness to pegloticase in patients with chronic refractory gout","volume":"79","author":"Rainey","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"3S","key":"R49-20251007","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.semarthrit.2020.04.011","article-title":"Pegloticase treatment of chronic refractory gout: update on efficacy and safety","volume":"50","author":"Schlesinger","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R50-20251007","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.semarthrit.2012.03.010","article-title":"Treatment of chronic gouty arthritis: it is not just about urate-lowering therapy","volume":"42","author":"Schlesinger","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"R51-20251007","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"R52-20251007","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"R53-20251007","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/annrheumdis-2024-eular.1866","article-title":"Canakinumab prophylaxis without corticosteroids, prevented flares in patients initiating pegloticase with methotrexate for uncontrolled gout: a prospective, multicenter, open label, proof-of-concept, phase IV, clinical trial","volume":"83","author":"Botson","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R54-20251007","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fimmu.2020.00969","article-title":"Development of ImmTOR tolerogenic nanoparticles for the mitigation of antidrug antibodies","volume":"11","author":"Kishimoto","year":"2020","journal-title":"Front Immunol"},{"key":"R55-20251007","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40744-023-00546-0","article-title":"Phase 2 dose-finding study in patients with gout using SEL-212, a novel PEGylated uricase (SEL-037) combined with tolerogenic nanoparticles (SEL-110)","volume":"10","author":"Kivitz","year":"2023","journal-title":"Rheumatol Ther"},{"key":"R56-20251007","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/rheumatology\/kead333","article-title":"The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR) versus pegloticase for refractory gout","volume":"63","author":"Baraf","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R57-20251007","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/annrheumdis-2024-eular.2832","article-title":"Once-monthly Sel-212 demonstrates efficacy and safety for up to 6-months in gout refractory to conventionaltherapy: combined data from the dissolve I & II phase 3, double-blind, placebo-controlled clinical trials","volume":"83","author":"Baraf","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"R58-20251007","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/annrheumdis-2024-eular.2875","article-title":"Long-term improvements in serum uric acid levels, gout symptoms, and safety upto 12-months with Sel-212 in gout refractory to conventional therapy: results from the dissolve I phase 3, double-blind, placebo-controlled clinical trial","volume":"83","author":"Kivitz","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"R59-20251007","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.taap.2015.06.004","article-title":"Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R","volume":"287","author":"Atsmon","year":"2015","journal-title":"Toxicol Appl Pharmacol"},{"key":"R60-20251007","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/pbi.12702","article-title":"Establishment of a tobacco BY2 cell line devoid of plant-specific xylose and fucose as a platform for the production of biotherapeutic proteins","volume":"15","author":"Hanania","year":"2017","journal-title":"Plant Biotechnol J"},{"issue":"Suppl 9","key":"R61-20251007","article-title":"Prolonged plasma urate-lowering after a single intravenous administration of PRX-115, a novel PEGylated uricase, in participants with elevated urate levels [abstract]","volume":"76","author":"Schwabe","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:00:44Z","timestamp":1759813244000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000001122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000001122","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}